In the original article, there was a mistake in Figure 1 and Table 2 as published. Duplicated panels were contained in Figure 1 due to author error. The authors provided a modified Figure 1 during the review process. The data of the pre-experiment were misplaced in Table 2 and submitted after the proofs due to author error. The corrected Figure 1 and Table 2 appear below.
Figure 1
Table 2
| No. | Tumor volume (mm3) | Control group | RT | RT+DDP | RT+Anlotinib | RT+DDP+Anlotinib |
|---|---|---|---|---|---|---|
| PDX1 | Initial | 266.64 ± 37.05 | 243.4 ± 31.38 | 252.61 ± 60.13 | 260.90 ± 43.67 | 267.24 ± 51.13 |
| Final | 343.51 ± 29.22 | 188.54 ± 40.04 | 150.31 ± 15.87 | 144.29 ± 15.05 | 121.02 ± 25.72 | |
| Changing | 77.06 ± 32.90 | −54.95 ± 39.63 | −102.31 ± 46.44 | −116.61 ± 45.17 | −146.23 ± 48.59 | |
| PDX2 | Initial | 187.52 ± 62.04 | 171.5 ± 31.30 | 185.45 ± 44.30 | 178.06 ± 40.02 | 181.31 ± 15.67 |
| Final | 246.07 ± 109.69 | 116.3 ± 25.17 | 133.11 ± 53.32 | 119.17 ± 30.60 | 71.79 ± 5.88 | |
| Changing | 58.55 ± 64.42 | −55.11 ± 22.68 | −52.34 ± 55.52 | −58.89 ± 38.21 | −109.52 ± 18.05 | |
| PDX3 | Initial | 267.39 ± 28.18 | 265.4 ± 57.22 | 267.33 ± 53.02 | 256.01 ± 30.76 | 262.82 ± 29.66 |
| Final | 648.68 ± 222.59 | 130.7 ± 57.33 | 161.87 ± 45.37 | 124.46 ± 38.87 | 70.89 ± 15.46 | |
| Changing | 381.33 ± 251.804 | −134 ± 17.26 | −105.46 ± 13.90 | −131.54 ± 35.45 | −191.93 ± 42.70 | |
| No. | Body weight (g) | Control group | RT | RT+DDP | RT+Anlotinib | RT+DDP+Anlotinib |
| PDX1 | Initial | 25.92 ± 22.15 | 24.85 ± 2.06 | 26.3 ± 41.20 | 24.7 ± 81.34 | 24.29 ± 1.57 |
| Final | 25.99 ± 0.50 | 24.77 ± 2.30 | 25.9 ± 62.02 | 23.9 ± 12.47 | 23.45 ± 2.27 | |
| Changing | 0.06 ± 2.53 | −0.08 ± 0.73 | −0.88 ± 1.84 | −0.87 ± 2.56 | −0.83 ± 1.39 | |
| PDX2 | Initial | 22.68 ± 1.79 | 22.25 ± 0.84 | 22.66 ± 1.08 | 22.32 ± 1.48 | 22.71 ± 2.71 |
| Final | 24.07 ± 0.77 | 23.35 ± 1.82 | 23.03 ± 1.01 | 22.05 ± 1.87 | 23.29 ± 1.47 | |
| Changing | 1.60 ± 1.23 | 1.10 ± 1.21 | 0.37 ± 0.84 | −0.27 ± 1.17 | 0.57 ± 1.46 | |
| PDX3 | initial | 22.00 ± 2.54 | 21.23 ± 2.77 | 20.86 ± 2.92 | 21.99 ± 2.70 | 22.05 ± 2.58 |
| Final | 24.21 ± 1.31 | 22.10 ± 1.30 | 22.86 ± 0.97 | 22.84 ± 1.07 | 22.69 ± 0.95 | |
| Changing | 2.21 ± 2.33 | 1.16 ± 1.72 | 2.00 ± 3.17 | 0.85 ± 3.15 | 0.64 ± 3.11 |
The detailed data of tumor volume and body weight.
RT, radiation therapy; DDP, cisplatin.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
patient-derived xenograft, esophageal squamous cell carcinoma, anlotinib, chemoradiotherapy, anti-angiogenesis
Citation
Shi J, Zhang Y, Wang J, Li J and Li Z (2020) Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma. Front. Oncol. 10:583499. doi: 10.3389/fonc.2020.583499
Received
15 July 2020
Accepted
10 September 2020
Published
20 November 2020
Volume
10 - 2020
Edited and reviewed by
Massimo Broggini, Mario Negri Pharmacological Research Institute (IRCCS), Italy
Updates
Copyright
© 2020 Shi, Zhang, Wang, Li and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jianbin Li lijianbin@msn.comZhenxiang Li lizx0108@163.com
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.